Clinical Trials Logo

Gender Dysphoria clinical trials

View clinical trials related to Gender Dysphoria.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05428215 Terminated - Gender Dysphoria Clinical Trials

Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

Start date: December 29, 2022
Phase: Phase 4
Study type: Interventional

This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.

NCT ID: NCT04551144 Terminated - Transgenderism Clinical Trials

Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors

Start date: October 6, 2020
Phase:
Study type: Observational

The purpose of this research is to find out if hormone therapy in transgender subjects' changes hormone receptors in blood, muscle and fat; fat production; muscle production; and inflammation processes.

NCT ID: NCT04374708 Terminated - Gender Dysphoria Clinical Trials

Gender Identity and Own Body Perception

Start date: February 22, 2018
Phase:
Study type: Observational

This study will provide valuable information on the neurobiological underpinning of gender dysphoria (GD) and the effects of sex hormones, and promises to uncover functional or structural neural patterns that could predict outcome in terms of body image and quality of life after cross-sex hormone treatment.

NCT ID: NCT03078829 Terminated - Gender Dysphoria Clinical Trials

The Relation of GnRH Treatment to QTc Interval in Transgender Females

Start date: May 1, 2017
Phase:
Study type: Observational

Background: The QT interval of the electrocardiogram (ECG), corrected for heart rate (QTc), is a measure of the duration of ventricular repolarization and is a widely used marker of ventricular arrhythmia risk. Testosterone has a shortening effect on QTc length, and the QTc interval in males is shorter than in females after the onset of puberty. Transgender female adolescents are treated with GnRH agonists or spironolactone that suppress endogenous testosterone secretion and might increase the QT interval sufficiently to increase the risk for malignant ventricular arrhythmias. There are no current guidelines regarding monitoring QTc interval in transgender females undergoing GnRH agonist treatment. Objective: To assess the effect of GnRH agonist treatment on QTc interval in transfemale youth. Methods: A quasi-experimental time series study of transgender female adolescent, seen at UCSF Child and Adolescent Gender Center (CAGC) during 2017-2019. Specific aims: To assess the impact of GnRH agonist treatment on QTc interval length in transgender female adolescent